Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
breast tissue
|
| gptkbp:current_use |
metastasis
lymphedema |
| https://www.w3.org/2000/01/rdf-schema#label |
invasive ductal carcinoma
|
| gptkbp:is_a |
gptkb:healthcare_organization
|
| gptkbp:is_popular_in |
most common type of breast cancer
|
| gptkbp:number_of_stages |
Stage 0
Stage I Stage II Stage III Stage IV |
| gptkbp:research_focus |
gptkb:vaccine
biomarkers personalized medicine targeted therapies |
| gptkbp:risk_factor |
age
alcohol consumption obesity family history genetic mutations |
| gptkbp:screenings |
annual mammograms after age 40
|
| gptkbp:social_responsibility |
biopsy
depends on stage mammography depends on grade depends on HE R2 status depends on hormone receptor status |
| gptkbp:symptoms |
lump in the breast
nipple discharge change in breast shape |
| gptkbp:treatment |
gptkb:hospital
radiation therapy chemotherapy hormone therapy HE R2 positive may respond to targeted therapy hormone receptor positive has better prognosis recurrence risk varies by subtype response to chemotherapy varies by subtype survival rate varies by stage |
| gptkbp:type_of |
HE R2-enriched
luminal A luminal B triple-negative |